DEVICE AND METHOD FOR RESTORATION OF THE CONDITION OF BLOOD

• US 20140131276A1
• Filed: 01/15/2014
• Published: 05/15/2014
• Est. Priority Date: 06/18/2007
• Status: Active Grant

• Current Assignee: ExThera Medical Corporation
• Original Assignee: ExThera Medical Corporation
• Inventors: WARD, Robert S., LARM, Olle, Bergstrm, Tomas, AXELSSON, Jonas, ADOLFSSON, Lars, MCCREA, Keith
• Granted Patent: US 9,669,150 B2
• Time in Patent Office: Days
• US Class Current: 210/635
• CPC Class Codes: A61K 8/0208 Tissues; Wipes; Patches
• CPC Class Codes: A61K 8/33 containing oxygen
• CPC Class Codes: A61K 8/34 Alcohols
• CPC Class Codes: A61K 8/342 Alcohols having more than seven atoms in an unbroken chain
• CPC Class Codes: A61K 8/35 Ketones, e.g. benzophenone
• CPC Class Codes: A61M 1/3621 Extra-corporeal blood circuits single-needle circuits A61M1/30
• CPC Class Codes: A61M 1/3672 Means preventing coagulation
• CPC Class Codes: A61Q 13/00 Formulations or additives for perfume preparations essential oils or perfumes per se C11B9/00
• CPC Class Codes: A61Q 15/00 Anti-perspirants or body deodorants deodorisation of air A61L9/00
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin
• CPC Class Codes: A61Q 19/10 Washing or bathing preparations
• CPC Class Codes: A61Q 5/00 Preparations for care of the hair

Abstract

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood com-Components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

Claims

1-41. -41. (canceled)

42. Apparatus for extracorporeal circulation of blood or blood components, comprising a conventional extracorporeal blood treatment device and a device for removal of harmful agents, wherein said device for removal of harmful agents comprises heparin immobilized on a solid substrate by covalent end point attachment.

43. Apparatus according to claim 42, wherein said device for removal of harmful agents is arranged downstream of the conventional extracorporeal blood treatment device.

44. Apparatus according to claim 42, wherein said heparin is covalently end point attached full length heparin.

45. Apparatus according to claim 44, wherein said full length heparin has a mean molecular weight in the range of 15-25 kDa.

46. Apparatus according to claim 44, wherein said full length heparin has a mean molecular weight of more than 21 kDa.

47. Apparatus according to claim 44, wherein the surface concentration of said full length heparin is 1-20 μ

g/cm².

48. Apparatus according to claim 47, wherein the surface concentration of said full length heparin is 5-15 μ

g/cm².

49. Apparatus according to claim 42, wherein said heparin is covalently attached to said solid substrate via stable secondary amino groups.

50. Apparatus according to claim 42, wherein the total surface area of said solid substrate is in the range of 0.1-20 m².

51. Apparatus according to claim 50, wherein the total surface area of said solid substrate is in the range of 0.5-3 m².

52. Apparatus according to claim 50, wherein said solid substrate comprises particles or beads.

53. Apparatus according to claim 52, wherein the particle or bead diameter is in the range of 10-1000 μ

m.

54. Apparatus according to claim 52, wherein the particle or bead diameter is in the range of 20-200 μ

m.

55. Apparatus according to claim 52, wherein said particle or bead comprises a material selected from the group consisting of polyurethanes, polyolefins, silicones, fluoropolymers, poly(methyl methacrylate), glass, cross linked alginates, and cross linked polysaccharides, such as agarose, dextran, cellulose, chitosan and starch.

56. Apparatus according to claim 42, wherein said solid substrate comprises one or more hollow fibers.

57. Apparatus according to claim 56, wherein the inner diameter of said hollow fiber is in the range of 10-1000 μ

m.

58. Apparatus according to claim 56, wherein the inner diameter of said hollow fiber is in the range of 20-200 μ

m.

59. Apparatus according to claim 56, wherein said hollow fiber comprises a material selected from the group consisting of polysulfones, polyamides, polynitriles, polypropylenes, cross linked alginates, and cellulose.

60. Apparatus according to claim 42, wherein the device is a column comprising a casing containing the heparinized solid substrate, said column having an inlet through which blood may enter the column and an outlet through which blood may exit the column and said inlet and outlet are arranged such that blood entering through the inlet is brought into contact with said heparinized solid substrate before it exits the column through the outlet.

61. A method for hemodialysis which comprises contacting blood from a patient in need thereof with the apparatus according to claim 42.

62. A method for oxygenation of blood which comprises contacting blood with an apparatus according to claim 42.

63. A method for the extracorporeal treatment of blood or blood components which comprises contacting blood with an apparatus according to claim 42.

64. A method for oxygenation of blood which comprises contacting blood from a patient in need of thereof with the apparatus according to claim 42.

65. A method for the treatment of acute sepsis which comprises contacting blood from a patient suspected of suffering from acute sepsis to an apparatus according to claim 42.

66. The method according to claim 63, wherein said blood is contacted with said apparatus at a blood flow rate of 2000-7000 mL/min.

67. The method according to claim 61, wherein said blood is contacted with said apparatus at a blood flow rate of 200-500 mL/min.

68. The method according to claim 64, wherein said blood is contacted with said apparatus at a blood flow rate of 1-100 mL/min.